News
Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...
New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs ...
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.
Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...
The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...
Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...
14d
Stocktwits on MSNHims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s DullShares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...
Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new deal for copay caps on Eli Lilly (LLY) and Novo Nordisk (NVO) weight loss ...
Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.
Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results